Mean scores for patient-reported outcomes during the double-blind and open-label treatment periods. Data given under “placebo” refer to placebo-etanercept during the open-label phase. Data under “etanercept” refer to continued etanercept during the open-label phase. No imputation was used for missing data during the open-label phase.
| HAQ-DI | EQ-5D | SF-36 PCS | SF-36 MCS | ACR Pain | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean (SE) | Mean (SE) | Mean (SE) | Mean (SE) | Mean (SE) | ||||||
| Time | placebo | etanercept | placebo | etanercept | placebo | etanercept | placebo | etanercept | placebo | etanercept |
| Baseline | 1.1 (0.1) | 1.1 (0.1) | 62.0 (2.2) | 64.7 (2.0) | 35.7 (0.9) | 35.8 (1.0) | 48.4 (1.1) | 50.9 (1.2) | 3.0 (0.1) | 3.0 (0.1) |
| Week 24 of double-blind phase | 1.0 (0.1) | 0.5 (0.1) | 64.2 (2.2) | 79.0 (1.7) | 36.4 (1.0) | 45.1 (1.1) | 48.4 (1.2) | 53.6 (0.9) | 2.8 (0.1) | 1.6 (0.1) |
| Start of open-label phase | 1.0 (0.1) | 0.4 (0.1) | 63.1 (2.5) | 81.6 (1.5) | 36.8 (1.1) | 46.4 (1.2) | 49.1 (1.3) | 53.7 (1.0) | 3.0 (0.1) | 1.4 (0.1) |
| Week 12 | 0.7 (0.1) | 0.5 (0.1) | 76.2 (2.0) | 81.7 (1.7) | 43.9 (1.2) | 46.7 (1.2) | 51.8 (1.2) | 52.8 (1.0) | 1.9 (0.1) | 1.5 (0.1) |
| Week 24 | 0.6 (0.1) | 0.4 (0.1) | 77.7 (2.0) | 82.1 (1.6) | 44.4 (1.1) | 47.0 (1.3) | 49.8 (1.3) | 51.6 (1.1) | 1.9 (0.1) | 1.4 (0.1) |
| Week 36 | 0.6 (0.1) | 0.4 (0.1) | 76.7 (2.0) | 82.6 (1.7) | 44.2 (1.2) | 46.0 (1.3) | 49.8 (1.3) | 53.6 (1.0) | 1.7 (0.1) | 1.4 (0.1) |
| Week 48 | 0.6 (0.1) | 0.4 (0.1) | 77.6 (1.9) | 83.6 (1.5) | 44.1 (1.3) | 47.3 (1.2) | 50.8 (1.3) | 53.5 (1.0) | 1.5 (0.1) | 1.3 (0.1) |
HAQ-DI: Health Assessment Questionnaire Disability Index; EQ-5D: EuroQol self-report questionnaire; SF-36 PCS: Short-Form 36 physical component summary; SF-36 MCS: Short-Form 36 mental component summary; ACR Pain: American College of Rheumatology patient pain assessment.